Low-dose colchicine for atherosclerosis: long-term safety

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Low-dose colchicine (0.5 mg daily) is FDA-approved for secondary prevention in coronary disease patients.
• Increasing clinical use necessitates understanding continuous low-dose colchicine safety.

Purpose of the Study:

• To inform physicians, pharmacists, and patients about the absolute risks of continuous low-dose colchicine use.
• To assess safety, including in patients taking statin therapy.

Main Methods:

• Collated data from systemic reviews of case reports, drug registries, and placebo-controlled trials.
• Focused on safety issues related to continuous colchicine use in various clinical settings.

Main Results:

• Continuous low-dose colchicine is well-tolerated and safe, with mild diarrhea as the primary transient side effect.
• No adverse effects on renal, liver, or cognitive function, bleeding, wound healing, fertility, or pregnancy.
• No increased risks of cancer, serious infection, or cause-specific mortality; rare myelosuppression/myotoxicity/drug interactions, similar to placebo.

Conclusions:

• Continuous low-dose colchicine is safe for cardiovascular risk reduction in patients without significant renal or hepatic impairment.
• Reassurance for healthcare providers and patients regarding the safety profile, even with statin co-therapy.